Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Masitinib||AB1010||KIT Inhibitor 50 LYN Inhibitor 3 PDGFR Inhibitor (Pan) 27||Masitinib (AB1010) inhibits several receptor tyrosine kinases including c-KIT, PDGFR, and LYN, which may result in inhibition of cell proliferation (PMID: 19789626, PMID: 29638149).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT00812240||Phase III||Masitinib Imatinib||A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment||Terminated|
|NCT02605044||Phase III||Masitinib Fluorouracil + Irinotecan + Leucovorin||Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer||Terminated|
|NCT01470131||Phase III||Masitinib Bortezomib + Dexamethasone||A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma||Terminated|
|NCT00814073||Phase III||Masitinib||A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap||Completed|